Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream
2020-003316-27Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Feb 2021
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imiquimod in actinic keratosis (AK), sponsored by Medical University of Graz. Primary endpoint: Primary: proportion with inflammatory reaction after imiquimod on UV-damaged facial skin. Started Feb 2021; status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2020-003316-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003316-27.